Tau at least partially mediates Aβ-induced BDNF downregulation. Therefore, Alzheimer’s disease treatments targeting Aβ alone may not be effective without considering the impact of Tau pathology on neurotrophic pathways. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.